Clinical Trials
20 trialsNCT05000294 2026-06-05
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Recruiting
NCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07288359 2026-06-04
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05417594 2026-06-02
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT04168528 2026-06-01
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Universitair Ziekenhuis Brussel
Phase 1/2 Terminated
NCT07612891 2026-05-29
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2 Recruiting
NCT07612215 2026-05-28
Elacestrant in Advanced Triple Positive Breast Cancer
NYU Langone Health
Phase 1/2 Recruiting
NCT06247995 2026-05-27
NeoB-Cap1
Novartis
Phase 1/2 Recruiting
NCT06324357 2026-05-26
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT06686394 2026-05-22
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07109726 2026-05-22
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT05900986 2026-05-20
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Integro Theranostics
Phase 1/2 Completed
NCT06502691 2026-05-19
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT07596212 2026-05-19
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
Phase 1/2 Not yet recruiting
NCT05123482 2026-05-18
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
Phase 1/2 Recruiting
NCT07100106 2026-05-18
MoonROSE
Genentech, Inc.
Phase 1/2 Recruiting
NCT06827236 2026-05-15
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
BioNTech SE
Phase 1/2 Recruiting